Ioflupan (123i) Rotop

Ioflupane, the active ingredient in Ioflupan (123i) Rotop, is a radiopharmaceutical presented as an injectable solution for intravenous use. It enables imaging of dopamine transporters to aid diagnosis of Parkinsonian syndromes and other movement disorders.

GNH USA supplies Ioflupan (123i) Rotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and imaging centres worldwide.

Ioflupan (123i) Rotop is used in the evaluation of dopaminergic neuronal integrity within the Parkinsonian disease spectrum and related movement disorders. - Parkinsonian syndromes: provides visualization of presynaptic dopaminergic neuron integrity to support diagnosis. - Differential diagnosis of movement disorders: helps distinguish Parkinson's disease from essential tremor and atypical parkinsonism. - Clinical research of the dopaminergic system: enables quantitative assessment of dopamine transporter density in investigational studies.

Ioflupan (123i) Rotop may cause adverse reactions related to the injection and the radioactive tracer.

Common Side Effects: - Injection site pain: mild discomfort at the venipuncture site. - Nausea: transient feeling of queasiness. - Headache: mild to moderate headache after administration. - Transient flushing: brief warmth or redness of the skin.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure post‑injection. - Radiation‑induced thyroid dysfunction: potential alteration of thyroid hormone levels. - Seizure: rare occurrence of convulsive activity.

Before using Ioflupan (123i) Rotop, consider the following safety measures. - Pregnancy: safety unknown; avoid unless essential for diagnosis. - Breastfeeding: safety unknown; consider discontinuing breastfeeding. - Thyroid function: assess baseline thyroid status due to iodine content. - Renal impairment: evaluate renal function as the tracer is renally excreted. - Concomitant iodine contrast: avoid administration within 24 hours of iodinated contrast agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ioflupan (123i) Rotop may interact with other agents that affect iodine handling or physiological responses.

Major Interactions (Avoid): - Iodine‑containing contrast agents: can interfere with tracer uptake and imaging quality. - Thyroid hormone therapy: may alter iodine metabolism and affect imaging results.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask mild allergic reactions. - Diuretics: could modify renal clearance of the tracer. - Calcium channel blockers: potential influence on blood pressure during injection.